These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 25194004)

  • 1. Paricalcitol for secondary hyperparathyroidism in renal transplantation.
    Trillini M; Cortinovis M; Ruggenenti P; Reyes Loaeza J; Courville K; Ferrer-Siles C; Prandini S; Gaspari F; Cannata A; Villa A; Perna A; Gotti E; Caruso MR; Martinetti D; Remuzzi G; Perico N
    J Am Soc Nephrol; 2015 May; 26(5):1205-14. PubMed ID: 25194004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Paricalcitol on Bone Density After Kidney Transplantation: Analysis of 2 Transplant Centers.
    Žilinská Z; Dedinská I; Breza J; Laca L
    Iran J Kidney Dis; 2017 Nov; 11(6):461-466. PubMed ID: 29190607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
    Jamaluddin EJ; Gafor AH; Yean LC; Cader R; Mohd R; Kong NC; Shah SA
    Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients.
    Dusilová-Sulková S; Šafránek R; Vávrová J; Horáček J; Pavlíková L; Palička V
    Int Urol Nephrol; 2015 Jan; 47(1):169-76. PubMed ID: 25262147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
    Biggar P; Kovarik J; Klauser-Braun R; Graf H; Müller HW; Veres A; Seidinger S; Ketteler M
    Nephron Clin Pract; 2014; 126(1):39-50. PubMed ID: 24458019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised clinical study of alfacalcidol and paricalcitol.
    Hansen D
    Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis.
    Sánchez-Álvarez JE; Rodríguez-Suárez C; Coronel-Aguilar D; González-Díaz I; Núñez-Moral M; Peláez-Requejo B; Fernández-Viña A; Quintana-Fernández A
    Nefrologia; 2013 Jan; 33(1):70-6. PubMed ID: 23364628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic bead-based proteomic technology to study paricalcitol effect in kidney transplant recipients.
    Pérez V; Sánchez-Escuredo A; Lauzurica R; Bayés B; Navarro-Muñoz M; Pastor MC; Cañas L; Bonet J; Romero R
    Eur J Pharmacol; 2013 Jun; 709(1-3):72-9. PubMed ID: 23567070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correction of secondary hyperparathyroidism with paricalcitol in renal transplant improves left ventricular hypertrophy].
    Massimetti C; Imperato G; Feriozzi S
    G Ital Nefrol; 2019 Feb; 36(1):. PubMed ID: 30758155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral paricalcitol on hyperparathyroidism and proteinuria in peritoneal dialysis patients.
    Coronel F; Rodríguez-Cubillo B; Cigarrán S; Gomis A
    Adv Perit Dial; 2011; 27():130-3. PubMed ID: 22073844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
    Fernström A; Giæver J; Granroth B; Hylander B; Jensen G; Christensson A; Wikström B; Weiss L; Wrege U; Jacobson SH
    Scand J Urol Nephrol; 2011 Apr; 45(3):196-205. PubMed ID: 21366390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paricalcitol versus placebo for reduction of proteinuria in kidney transplant recipients: a double-blind, randomized controlled trial.
    Oblak M; Mlinšek G; Kandus A; Buturović-Ponikvar J; Arnol M
    Transpl Int; 2018 Dec; 31(12):1391-1404. PubMed ID: 30062716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory profile of paricalcitol in kidney transplant recipients.
    Donate-Correa J; Henríquez-Palop F; Martín-Núñez E; Hernández-Carballo C; Ferri C; Pérez-Delgado N; Muros-de-Fuentes M; Mora-Fernández C; Navarro-González JF
    Nefrologia; 2017; 37(6):622-629. PubMed ID: 28623033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
    Fishbane S; Chittineni H; Packman M; Dutka P; Ali N; Durie N
    Am J Kidney Dis; 2009 Oct; 54(4):647-52. PubMed ID: 19596163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
    Sharma A; Marshall TS; Khan SS; Johns B
    Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism.
    Egido J; Martínez-Castelao A; Bover J; Praga M; Torregrosa JV; Fernández-Giráldez E; Solozábal C
    Nefrologia; 2016; 36(1):10-8. PubMed ID: 26705959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients.
    Donate-Correa J; Henríquez-Palop F; Martín-Núñez E; Pérez-Delgado N; Muros-de-Fuentes M; Mora-Fernández C; Navarro-González JF
    Transplantation; 2016 Nov; 100(11):2432-2438. PubMed ID: 27467536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.